Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–36
Headlines
41
Sources here
2
Companies here
7
Current section Denmark Healthcare news
Latest

finance.yahoo.com Market update

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by …

Main company 🇩🇰 Denmark
Read at finance.yahoo.com
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Provider-linked mention 🇩🇰 Denmark

Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026

ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at …

ALK-B mentioned
Sharemaestro market context Trend signal ended 52 weeks +23.3% ALK-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non-recurring items. This …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇩🇰 Denmark

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇩🇰 Denmark

Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Demant AS (WILLF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth Fueled by Oticon Zeal ...

This article first appeared on GuruFocus. Revenue Growth: Group reported growth of 15% in H1 2026, with 7% organic growth and 10% acquisitive growth, primarily from KIND. Gross Margin: Increased by 1.1 percentage points, driven by strong ASP in hearing aids and the acquisition …

DEMANT main company
Sharemaestro market context Trend signal active 52 weeks +14.4% DEMANT stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Analyst action Main company 🇩🇰 Denmark

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …

GMAB main company
Sharemaestro market context Price above Trend Line 52 weeks +33.5% GMAB stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇩🇰 Denmark

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
nasdaq.com Analyst action Main company 🇩🇰 Denmark

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NOVO-B main company
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. …

ZEAL mentioned
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future …

ZEAL main company
Sharemaestro market context Price above Trend Line 52 weeks -10.8% ZEAL stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇩🇰 Denmark

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

CHEMM main company
Sharemaestro market context Price above Trend Line 52 weeks -13.3% CHEMM stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

New Beltone Illuminate Hearing Aids Automatically Adapt to Noise, Helping People Hear More Clearly in Everyday Life

Premium hearing aids' technological advancement prioritizes what users want to hear – clearly in noisy situations CHICAGO, Aug. 10, 2026 /PRNewswire/ -- . Following conversations in noisy restaurants, family gatherings, and other busy environments can be one of the biggest challenges for people with …

GN mentioned
Sharemaestro market context New activity signal 52 weeks +0.8% · Next-week setup negative 43.6% GN stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇩🇰 Denmark

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

NOVO-B mentioned
Sharemaestro market context Trend signal started 52 weeks -3.2% NOVO-B stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context